Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

Stopped poor enrollment likely due to expanded availability of immunotherapy for patients

Conditions

• Cancer
• Rare Disease

Interventions

• DRUG: Durvalumab
• DRUG: Tremelimumab

Sponsor

Prisma Health-Upstate

Collaborators

• [object Object]
• [object Object]